Scancell Holdings Plc, which is developing immunotherapies for cancer, has appointed Sally Adams as director of development. Dr Adams has been working as a consultant to the company since 2008 during which period she helped execute clinical development plans for the company’s lead product for melanoma. Previously she was head of neurology and virology at British Biotech and before that development director at Neures Ltd. Dr Adams holds an MA in genetics from the University of Cambridge and a PhD in microbiology from Imperial College London.
Scancell announced the appointment on 1 May 2014.
Copyright 2014 Evernow Publishing Ltd